August 22, 2024 08:00 AM EDT
Financing
Startups
Pharma

Ver­sant and No­var­tis build 'Chi­nook 2.0' for RNA ther­a­pies in kid­ney dis­eases

Kyle LaHucik

Senior Reporter

Five years to the day af­ter launch­ing Chi­nook Ther­a­peu­tics, Ver­sant Ven­tures is back with a sec­ond gen­er­a­tion of that kid­ney dis­ease biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Ex­clu­sive: Mod­er­na's for­mer top sci­en­tist has a new start­up us­ing AI to im­prove mR­NA ther­a­pies

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

A service from the Financial Times